Compare ABCL & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABCL | PHAT |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 942.6M |
| IPO Year | 2020 | 2019 |
| Metric | ABCL | PHAT |
|---|---|---|
| Price | $4.12 | $15.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $7.75 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 3.5M | 911.3K |
| Earning Date | 02-26-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $35,325,000.00 | ★ $147,190,000.00 |
| Revenue This Year | $25.45 | $220.37 |
| Revenue Next Year | $10.07 | $83.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 7.17 | ★ 460.30 |
| 52 Week Low | $1.89 | $2.21 |
| 52 Week High | $6.52 | $18.31 |
| Indicator | ABCL | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 62.59 | 47.30 |
| Support Level | $3.34 | $15.43 |
| Resistance Level | $4.20 | $18.09 |
| Average True Range (ATR) | 0.21 | 0.91 |
| MACD | 0.09 | -0.13 |
| Stochastic Oscillator | 88.37 | 12.66 |
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.